FDA warned Cosco International over nonprescription drug manufacturing failures and unapproved drug products.
What happened
FDA inspected Cosco International’s Marietta, Georgia drug manufacturing facility from October 15 to 25, 2024. The agency found inadequate process and cleaning validation, insufficient stability data, inadequate testing of water used in drug products, and quality-unit oversight failures. FDA also reviewed product labeling and found Carpe Antiperspirant Foot and Hand Lotions and a redacted skin protectant were unapproved new drugs and misbranded (illegally labeled); the company had not responded to the inspection observations FDA cited on its Form FDA 483 (inspection findings form).
What FDA found
Failed to validate manufacturing processes for OTC drugs, including children’s wound gel and ear flush, before commercial distribution.
21 CFR 211.100(a)Failed to validate cleaning of shared equipment used for drugs and cosmetics, so cross-contamination was not ruled out.
21 CFR 211.100(a)Lacked adequate stability data to show drug products, including children’s wound products, met specifications through their labeled shelf-life.
21 CFR 211.166(a)Failed to adequately test and validate testing of water used as a drug ingredient for bacteria, fungi, and objectionable organisms, and used a nonrepresentative sampling point.
21 CFR 211.160(b)Quality control unit did not adequately oversee the stability program, expired raw-material controls, and computerized record access.
21 CFR 211.22Marketed unapproved new drugs and misbranded (illegally labeled) products because the skin protectant combined active ingredients not allowed by OTC monograph M016 and the Carpe products claimed hand and foot use not allowed by M019.
FD&C Act §§505(a), 301(d), 502(ee), 505G; 21 U.S.C. 355(a), 331(d), 352(ee), 355h
What FDA wants
FDA tells Cosco to correct the violations promptly and respond in writing within 15 working days with the actions taken and steps to prevent recurrence. If corrections cannot be completed in that time, the firm must state why and give a completion schedule; FDA also recommends a qualified current good manufacturing practice (CGMP) consultant and a six-system audit.
Who should pay attention
- brands whose OTC drugs are made by Cosco
- sellers of Carpe antiperspirant products
- makers of children’s OTC wound-care drugs
This is a summary. Read the original letter on fda.gov.